KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non Operating Income (2016 - 2025)

Alnylam Pharmaceuticals' Non Operating Income history spans 16 years, with the latest figure at $138.2 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 255.6% year-over-year to $138.2 million; the TTM value through Dec 2025 reached $54.1 million, up 127.52%, while the annual FY2025 figure was $5.2 million, 102.6% up from the prior year.
  • Non Operating Income reached $138.2 million in Q4 2025 per ALNY's latest filing, up from -$74.1 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $189.3 million in Q4 2022 to a low of -$171.9 million in Q4 2021.
  • Average Non Operating Income over 5 years is -$24.4 million, with a median of -$34.9 million recorded in 2022.
  • Peak YoY movement for Non Operating Income: crashed 1595.22% in 2021, then surged 255.6% in 2025.
  • A 5-year view of Non Operating Income shows it stood at -$171.9 million in 2021, then surged by 210.12% to $189.3 million in 2022, then tumbled by 110.75% to -$20.4 million in 2023, then plummeted by 336.34% to -$88.8 million in 2024, then soared by 255.6% to $138.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Non Operating Income are $138.2 million (Q4 2025), -$74.1 million (Q3 2025), and -$19.2 million (Q2 2025).